

## Targeting RNA structure in SMN2 reverses Spinal Muscular Atrophy molecular phenotypes

A. Garcia-Lopez<sup>1</sup>, F. Tessaro<sup>1</sup>, H. Jonker<sup>2</sup>, A. Wacker<sup>2</sup>, C. Richter<sup>2</sup>, A. Comte<sup>3</sup>, B. Joseph<sup>3</sup>, H. Schwalbe<sup>2</sup>, L. Liu<sup>1\*</sup>

<sup>1</sup>Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Geneva, Switzerland, <sup>2</sup>Institut für Organische Chemie und Chemische Biologie, Center for Biomolecular Magnetic Resonance (BMRZ), Johann Wolfgang Goethe-University Frankfurt, Frankfurt, Germany, <sup>3</sup>Institut de Chimie et Biochimie Moléculaires et Supramoléculaires (ICBMS) UMR CNRS 5246, University of Lyon, University Claude Bernard Lyon 1, Villeurbanne, France

Modification of *SMN2* exon 7 (E7) splicing to increase SMN protein production is a validated therapeutic strategy against Spinal Muscular Atrophy (SMA). Based on this, we have performed the first small molecule screening described for SMA, choosing a stem-loop RNA structure TSL2 that partially overlaps with the E7 5' splicing site (5' ss) of *SMN2* as the biological target. TSL2-binding hit PK4C9 was found to also increase E7 splicing and rescued downstream molecular alterations in transfected HeLa cells, transgenic *Drosophila*, and SMA patient cells. High-resolution NMR combined with *in silico* modeling revealed that PK4C9 binding to TSL2 promotes a conformational shift towards a triloop conformation, which we also demonstrate that is associated with an enhanced E7 splicing efficiency. This work not only provides one of the few examples of small molecules with direct *SMN2*-splicing modifier activity, but also opens new avenues for rational drug discovery in SMA and other splicing-mediated diseases where similar RNA structures are involved.